Enhancement of dissolution rate and formulation development of irbesartan tablets by employing starch phosphate: A new modified starch

Veeraiah Enturi, B. Yaminipurna Chowdary, K. P. R. Chowdary

Abstract


The objective of the present study is to prepare, characterize, and evaluate starch phosphate as a carrier in solid dispersions
for enhancing the dissolution rate of irbesartan (IRB). The feasibility of formulating solid dispersions of IRB in starch
phosphate into compressed tablets with enhanced dissolution rate was also investigated. Starch phosphate prepared by
reacting starch with di‑sodium hydrogen orthophosphate anhydrous at elevated temperatures was insoluble in water and
has good swelling (400%) property without pasting or gelling when heated in water. Solid dispersions of IRB in starch
phosphate prepared by solvent evaporation method employing various weight ratios of drug: Starch phosphate gave rapid
and higher dissolution of IRB when compared to pure drug. The 19.92‑ and 39.98‑fold increase in the dissolution rate (K1)
of IRB was observed with solid dispersions ISD4 and ISD5, respectively. The dissolution efficiency up to 30 min (DE30) was
also increased from 10.58% in the case of IRB pure drug to 81.77% and 88.28% in the case of ISD4 and ISD5, respectively.
IRB tablets formulated employing its solid dispersions in starch phosphate also gave rapid and higher dissolution rate and
DE30 when compared to plain and commercial tablets. The 33.82‑ and 59.66‑fold increase in the dissolution rate (K1) was
observed with formulations IBTF2 and IBTF3 when compared to formulation IBTF1. Starch phosphate could be used as a
carrier to enhance the dissolution rate of IRB from its solid dispersions as well as tablet formulations.
Key words: Irbesartan, solid dispersions, starch phosphate, tablets and modified starches

Full Text:

PDF

References


Sweetman SC. Martindale: The Complete Drug Reference. 34th ed.

London: Pharmaceutical Press; 2005. p. 940.

Pouleur HG. Clinical overview of irbesartan: A new angiotensin II

receptor antagonist. Am J Hypertens 1997;10:318S‑24S.

Chawla G, Bansal AK. A comparative assessment of solubility advantage

from glassy and crystalline forms of a water‑insoluble drug. Eur J Pharm

Sci 2007;32:45‑57.

Chowdary KP, Madhavi BL. Novel drug delivery technologies for

insoluble drugs. Indian Drugs 2005;42:557‑62.

Wurzburg OB. Modified starches. Properties and Uses. Boca Raton,

Florida: CRC Press Inc.; 1986. p. 277‑80.

Luallen TE. The use of starches in frozen food formulation. Food Technol

;48:39‑43.

Salay E, Ciacco CF. Production and properties of starch phosphate

produced by the extrusion process. Starch/Starke 1990;42:15‑7.

Chowdary KP, Enturi V. Enhancement of dissolution rate and formulation

development of efavirenz tablets employing starch phosphate a new

modified starch. Int J Pharm Sci Drug Res 2011;3:80‑3.

Chowdary KP, Enturi V, Rani AS. Formulation development of aceclofenac

tablets employing starch phosphate: A new modified starch. Int J Pharm

Sci Res 2011;2:124‑9.

Sung JH, Park DP, Park BJ, Choi HJ, Jhon MS. Phosphorylation of potato starch

and its electrorheological suspension. Biomacromolecules 2005;6:2182‑8.

Martin A. Micromeritics. In: Martin A, editor. Physical Pharmacy.

Baltimore, MD: Lippincott, Williams and Wilkins; 2001. p. 423‑54.

Cooper J, Gunn C. Tutorial pharmacy. In: Carter SJ, editor. Powder Flow

and Compaction. New Delhi, India: CBS Publications; 1986. p. 211‑33.

Aulton ME, Wells TI. Pharmaceutics. The Science of Dosage Form

Design. 2nd ed. London, England: Churchill Livingstone; 1988. p. 89‑90.

Khan KA. The concept of dissolution efficiency. J Pharm Pharmacol

;27:48‑9.




DOI: http://dx.doi.org/10.22377/ajp.v8i3.355

Refbacks

  • There are currently no refbacks.